John Sloan, MD
Hematology · Boston, MANPI 1659345320
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $229,645 of the $256,514 with a category attached, or 89.5%. Stemline Therapeutics Inc. accounts for 70.9% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2020 at $74,277 and has fallen 97.5% since, to $1,886 in 2025. Among hematology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 127 payments — averaging $2019.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stemline Therapeutics Inc.$182K
- ADC Therapeutics America, Inc.$13K
- EMD Serono, Inc.$11K
- Gilead$9K
- Acrotech Biopharma Inc.$9K
- Servier Pharmaceuticals LLC$7K
- plus $26K from 16 others
Across 11 payments — averaging $56,883 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seagen Inc.$319K
- Novartis$288K
- Acrotech Biopharma Inc.$18K
- Janssen Research & Development, LLC$1K
What the payments were for
- Consulting fees$229,64590%
- Speaking & faculty fees$4,1522%
- Travel & lodging$19,4888%
- Food & beverage$3,2081%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stemline Therapeutics Inc. | 47 | $181,970 |
| ADC Therapeutics America, Inc. | 13 | $13,326 |
| EMD Serono, Inc. | 3 | $10,700 |
| Gilead | 11 | $8,785 |
| Acrotech Biopharma Inc. | 5 | $8,571 |
| Servier Pharmaceuticals LLC | 10 | $7,192 |
| Seagen Inc. | 6 | $5,453 |
| AstraZeneca | 4 | $5,108 |
| Pharmacosmos Therapeutics Inc. | 2 | $4,152 |
| Bioverativ Therapeutics Inc. | 6 | $3,637 |
| Invivyd Inc | 1 | $2,625 |
| Novartis | 1 | $2,363 |
| Johnson & Johnson | 3 | $1,345 |
| Kyowa Kirin, Inc. | 4 | $374 |
| Sanofi | 2 | $275 |
| AbbVie | 2 | $126 |
| Amgen | 1 | $122 |
| Epizyme, Inc. | 1 | $121 |
| Pfizer | 2 | $102 |
| Daiichi Sankyo Inc. | 1 | $94 |
| Rigel Pharmaceuticals, Inc. | 1 | $53 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$256,514 in reported general payments places this provider in the 90th percentile of 77 hematology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 35 | $520,914 |
| PomalystPomalidomide | 19 | $381,018 |
| TasignaNilotinib Hcl | 14 | $194,290 |
| VenclextaVenetoclax | 13 | $167,574 |
| EliquisApixaban | 75 | $55,767 |
| XareltoRivaroxaban | 36 | $31,415 |
| Acyclovir | 21 | $263 |
| Dexamethasone | 19 | $102 |
| Prednisone | 21 | $95 |
| Pantoprazole Sodium | 14 | $36 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $21 | $381,01819 claims |
| NovartisTasigna | $2,363 | $194,29014 claims |
| AbbVieVenclexta | $126 | $167,57413 claims |
| PfizerEliquis | $102 | $55,76775 claims |
| Johnson & JohnsonXarelto | $1,345 | $31,41536 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 77 hematology providers in Massachusetts.
Other hematology in Boston
- Edward BenzBoston$747K
- David KuterBoston$543K
- Jacalyn RosenblattBoston$455K
- Lynn BryBoston$286K
- Andrew EvensBoston$217K
- Omar NadeemBoston$191K
- Nathan ConnellBoston$145K
- Jean ConnorsBoston$144K
- Heather BenjaminBoston$106K
- Martin SteinbergBoston$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.